LFSTHealthcare · Medical Care FacilitiesThe 11 Wall Street analysts covering Lifestance Health Group, Inc. hold a median 12-month price target of $15 — +5.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 4 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Lifestance Health Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Value (43): The shares cost a lot relative to the profits and assets behind them.
Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on LFST, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +5.6% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Oct 2026 | Keybanc | Maintains | Overweight | $13 → $15 |
| 10 Sept 2026 | Barclays | Maintains | Overweight | — |
| 10 Sept 2026 | Barclays | Maintains | Overweight | $13 → $15 |
| 9 Sept 2026 | Canaccord Genuity | Maintains | Buy | — |
| 9 Sept 2026 | Canaccord Genuity | Maintains | Buy | $13 → $15 |
| 19 Aug 2026 | BTIG | Maintains | Buy | $16 → $18 |
| 19 Aug 2026 | BTIG | Maintains | Buy | — |
| 14 Aug 2026 | JP Morgan | Maintains | Neutral | $9.00 → $13 |
| 14 Aug 2026 | JP Morgan | Maintains | Neutral | — |
| 7 Aug 2026 | BTIG | Maintains | Buy | — |
| 7 Aug 2026 | BTIG | Maintains | Buy | $15 → $16 |
| 24 July 2026 | BTIG | Maintains | Buy | — |
| 24 July 2026 | BTIG | Maintains | Buy | $12 → $15 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | $11 → $13 |
| 14 July 2026 | Barclays | Maintains | Overweight | — |
| 14 July 2026 | Barclays | Maintains | Overweight | $9.00 → $13 |
| 13 July 2026 | Keybanc | Maintains | Overweight | — |
| 13 July 2026 | Keybanc | Maintains | Overweight | $11 → $13 |
| 5 June 2026 | Goldman Sachs | Initiates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LFST appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Lifestance Health Group, Inc. returned +185.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 6% of US stocks
Cheaper than 35% of US stocks
Cheaper than 25% of US stocks
Cheaper than 6% of US stocks
Higher than 75% of US stocks
Higher than 98% of US stocks
Higher than 42% of US stocks
Higher than 59% of US stocks
Higher than 55% of US stocks
Higher than 50% of US stocks
Higher than 61% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lifestance Health Group, Inc. has a market value of $5.4B and an enterprise value of $5.4B.
Revenue in the twelve months to 30 June 2026: $1.6B. The latest quarter grew 26.1% year on year.
Net income over the same four quarters: $50.6M, a 3.2% net margin.
Free cash flow in the twelve months to 30 June 2026: $173.9M.
Trailing P/E: 109.3×; forward P/E: 33.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Lifestance Health Group, Inc. employs 8,542 people — $186K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lifestance Health Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
LifeStance Health Group announced financial results for the third quarter ended September 30, 2026, and raised its full-year outlook.
Why it matters — The quarterly results and updated outlook provide LFST watchers with the company’s latest reported performance and expectations.
LifeStance Health stock is approaching its latest buy point despite ongoing weakness in the broader stock market. Its relative strength line reached a new high last week.
Why it matters — LFST watchers may note the stock’s relative strength line reached a new high as it approaches the cited buy point.
LifeStance announced expanded U.S. access to esketamine (Spravato) and transcranial magnetic stimulation (TMS) for treatment-resistant depression. The company said separate analyses found meaningful reductions in depression symptoms and suicidal ideation among patients receiving the treatments.
Why it matters — The update highlights expansion of LifeStance’s specialty services and reported patient outcomes in treatment-resistant depression.
LifeStance Health Group said it will release its third-quarter 2026 earnings before the market opens on November 5, 2026, and host an earnings conference call that day.
Why it matters — LFST watchers can note the scheduled date for the company’s third-quarter earnings update and conference call.
Zacks Investment Research highlights gains by HF Sinclair, Accenture and FirstCash, citing its research portfolios amid market uncertainty and shifting investor sentiment.
Why it matters — The item does not discuss Lifestance Health Group, so it provides no company-specific information for LFST watchers.
The 11 Wall Street analysts covering Lifestance Health Group, Inc. have a median 12-month price target of $15, with estimates ranging from $12 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Lifestance Health Group, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lifestance Health Group, Inc. 92 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Lifestance Health Group, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +5.6% from the last close, and Ticker Nerd's factor model ranks Lifestance Health Group, Inc. 92 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lifestance Health Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LFST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $18 over the next 12 months.
Lifestance Health Group, Inc. returned +185.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
LifeStance Health Group, Inc. is a U.S.
The most recent item we track (GlobeNewsWire, 5 Nov 2026): "LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook". LifeStance Health Group announced financial results for the third quarter ended September 30, 2026, and raised its full-year outlook.
LifeStance Health Group, Inc. is a U.S. behavioral health services company that provides outpatient mental healthcare for children, adolescents, adults, and older patients. LifeStance offers psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. Its care model combines in-person visits at a broad network of centers with virtual appointments through its digital platform, giving patients access to coordinated mental health support across multiple settings. The company serves a wide range of common mental health needs through evidence-based, medically guided services delivered by licensed clinicians. LifeStance Health Group, Inc. focuses on outpatient care and operates as a single mental health services segment, making it a specialized provider within the healthcare market.
CEO Mr. David Patrick Bourdon · 8,542 employees · United States · https://lifestance.com
